NASDAQ · CYTK
Cytokinetics, Incorporated
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CYTK: Nov 04, 2026
Cytokinetics, Incorporated Common Stock is expected to report earnings on 11/04/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 9 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.5. The reported EPS for the same quarter last year was $-1.54.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.50 | $-1.39 | $-1.65 | 9 |
| Dec 2026 | $-1.51 | $-1.37 | $-1.57 | 8 |
| Mar 2027 | $-1.48 | $-1.34 | $-1.58 | 4 |
| Jun 2027 | $-1.38 | $-1.16 | $-1.57 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · MarketBeat · BNK Invest- Zacks · Oct 29, 9:00 AM EDTWill Alector (ALEC) Report Negative Q3 Earnings? What You Should KnowAlector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Oct 29, 4:01 AM EDTBiotech Stocks Facing FDA Decision In November 2026(RTTNews) – The FDA's November calendar has more than a dozen PDUFA dates on the horizon, setting the stage for an eventful month in the regulatory landscape.
- Zacks · Oct 28, 9:00 AM EDTCytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Oct 23, 10:53 AM EDTWeekly Buzz: AZN, ALVO Score FDA Nod; EYPT Cuts Jobs; RHHBY, GEHC Enter Deal; VERA Posts Trial Win(RTTNews) – Healthcare and biotech news this week centred on regulatory approvals, strategic deals, and pivotal clinical data.
- RTTNews · Oct 19, 9:58 AM EDTCytokinetics Adds Canada To MYQORZO's Growing List Of Approvals; Stock Up(RTTNews) – Cytokinetics, Incorporated (CYTK) announced that Health Canada has approved MYQORZO (aficamten) for treating adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) classified as New York Heart Association (NYHA) Class II-III.
- RTTNews · Oct 19, 9:52 AM EDTCytokinetics Wins Health Canada Approval For MYQORZO In Obstructive HCM(RTTNews) – Cytokinetics (CYTK) announced that Health Canada approved MYQORZO (aficamten) for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), NYHA Class II-III.
- Zacks · Oct 19, 8:40 AM EDTCan Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?Cytokinetics' Myqorzo gains commercial traction with growing prescriptions, international launches and promising clinical data that could expand its market opportunity.
- RTTNews · Oct 13, 1:10 AM EDTCytokinetics Highlights Exercise Capacity, Responder Data For Aficamten In NHCM At HFSA 2026(RTTNews) – Cytokinetics, Inc. (CYTK), a speciality cardiovascular biopharmaceutical company, announced that it presented additional data from ACACIA-HCM (Assessment Comparing aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM) at the Heart Failure Socie
- Zacks · Oct 2, 8:15 AM EDTWill Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?Bristol Myers' Camzyos gains a broader FDA label and strong sales growth, while emerging competitors and pipeline setbacks shape its cardiovascular outlook.
- MarketBeat · Sep 25, 10:02 AM EDTCytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein ConferenceAnalysts Think There's Still Time to Get in on Edgewise, Up 332%Cytokinetics (NASDAQ:CYTK) executives outlined the company’s commercial expansion plans, cardiovascular pipeline and business-development priorities during a Bernstein investor symposium, highlighting the launch of M
- BNK Invest · Sep 10, 10:49 AM EDTIWM, EAT, CYTK, ONB: ETF Outflow AlertLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 2000 ETF (Symbol: IWM) where we have detected an approximate $595.8 million dollar outflow — that's a 0.7% decrease week over week
- Zacks · Sep 4, 3:36 PM EDTWill Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?Bristol Myers??? Camzyos delivers durable five-year benefits, rising sales and potential adolescent label expansion.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Cytokinetics, Incorporated from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.